Verition Fund Management
NTLA icon

Verition Fund Management’s Intellia Therapeutics NTLA Stock Holding History

Verition Fund Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-32,297
Closed -$558K – 3818
2025
Q3 		$558K Sell
32,297
-76,308
-70% -$940K ﹤0.01% 2956
2025
Q2 		$1.02M Sell
108,605
-162,829
-60% -$1.34M 0.01% 2460
2025
Q1 		$1.93M Buy
271,434
+260,253
+2,328% +$2.63M 0.01% 1603
2024
Q4 		$130K Sell
11,181
-83,245
-88% -$1.3M ﹤0.01% 3047
2024
Q3 		$1.94M Buy
94,426
+50,763
+116% +$1.17M 0.01% 1436
2024
Q2 		$977K Buy
+43,663
New +$1.04M 0.01% 1681
2023
Q4 		– Sell
-13,200
Closed -$417K – 2589
2023
Q3 		$417K Buy
+13,200
New +$512K 0.01% 1541
2022
Q2 		– Sell
-6,079
Closed -$442K – 2873
2022
Q1 		$442K Buy
+6,079
New +$515K 0.01% 1960

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $127B AUM 43.98% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $121B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return